Clinical trials
Coronary Artery Disease Progression clinical trials
Below are recruiting coronary artery disease progression clinical trials, each written for real people, not researchers. We’re tracking 42 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06961136Recruiting
Herbal medicine for recovery after heart bypass surgery
This trial tests if a traditional Chinese herbal formula (Fuzheng Yangxin Prescription) can help people recover faster after coronary artery bypass surgery. It is for people who have a specific pattern of symptoms (called Qi-Yin deficiency) after their operation.
Beijing, Beijing MunicipalityAges 25–85 - NCT05618353RecruitingPhase 4
Colchicine before surgery to lower heart and inflammation complications
This trial tests whether taking colchicine around the time of surgery can reduce bad events after surgery in people at higher heart risk. It focuses on helping prevent complications related to inflammation after an operation.
Birmingham, AlabamaAges 18 years+ - NCT05762952RecruitingPhase 1
Dapagliflozin study for heart micro-blood-flow symptoms in women
This early-phase study tests whether dapagliflozin can improve tiny blood-vessel function in women who have heart-ache-like symptoms but no major blockage on heart scans. If it works, it may help symptoms related to “microvascular” heart circulation problems.
Charlottesville, VirginiaAges 18–99 - NCT07373119Enrolling by invitation
Frailty reduction in stable heart disease patients
This study tests a program to reduce frailty in older adults with stable coronary artery disease. The goal is to improve strength and well-being in people who are not having recent heart problems.
Barcelona, Select...Ages 70 years+ - NCT05852704RecruitingPhase 3
Dapagliflozin to prevent irregular heart rhythm after bypass surgery
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
BrnoAges 18 years+ - NCT06602934Recruiting
Pneumonia, heart health, and your body's germs
This study looks at how pneumonia affects the long-term health of your heart and lungs by studying the germs that live in your body. It may help doctors understand why some people get worse and how to better protect your heart after a serious infection.
AngersAges 18–80 - NCT04796506Recruiting
Tracking sleep changes to improve thinking in Parkinson’s
This study looks at whether changes in “slow wave sleep” (a deep sleep stage) match improvements in thinking for people with Parkinson’s. It uses an exercise/recovery-focused approach and checks sleep and thinking scores to see if these changes go together.
Aurora, ColoradoAges 45–100 - NCT06200311Recruiting
Atrial fibrillation ablation to prevent heart damage in women and men
This trial tests whether a procedure called AF ablation (which treats irregular heartbeats) can stop further damage to the heart muscle caused by atrial fibrillation. It may help people with both atrial fibrillation and early signs of heart muscle weakening.
GroningenAges 65–80 - NCT06527612Recruiting
Exercise's effect on lung disease and quality of life
This study looks at whether a personalized exercise program can improve quality of life and slow down lung disease in people with fibrosing interstitial lung disease. If you have trouble breathing when active and have been stable for the past month, you may be able to join.
Istanbul, ÜsküdarAges 18–75 - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new drug to standard care for prostate cancer
This trial tests a new study drug (AAA817) against the usual treatments for men with a certain type of advanced prostate cancer that has spread and is no longer responding to a targeted radiation therapy (177Lu-PSMA). The goal is to see if the new drug can help control the disease longer.
Los Angeles, CaliforniaAges 18–100 - NCT06923709RecruitingPhase 2
Amiloride for slowing kidney disease progression
This trial tests if the drug amiloride can help slow down chronic kidney disease. It may be an option if you have moderate kidney function and high protein in your urine.
OdenseAges 18 years+ - NCT06896708Recruiting
Intensive cholesterol treatment for heart plaque in younger adults
This trial tests whether higher doses of cholesterol-lowering medication (statins) can slow down plaque buildup in the heart arteries of younger and middle-aged adults with stable chest pain. It may help prevent heart attacks and the need for procedures like stents.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT05708859RecruitingPhase 4
Tirzepatide to slow plaque buildup in coronary arteries
This trial studies tirzepatide to see if it can slow the progression of coronary artery plaque in people with type 2 diabetes. It uses special heart CT scans to track changes over time.
Torrance, CaliforniaAges 40–80 - NCT07428447Recruiting
Skin test to predict Parkinson's risk in essential tremor
This study uses a skin biopsy to check for a protein linked to Parkinson's disease. It aims to see if people with essential tremor who have this protein are more likely to develop Parkinson's disease.
Scottsdale, ArizonaAges 50–85 - NCT06387017Recruiting
Can blood tests improve lung cancer screening in smokers with artery disease?
This study looks at whether certain blood tests can help find lung cancer early in people who have smoked for a long time and also have artery disease. The goal is to see if adding these tests to current screening methods can better identify those at highest risk.
MarseilleAges 45–80 - NCT06446531RecruitingPhase 1
Preventing diabetes progression in Hispanic adults
This trial tests if a medication can prevent or slow the progression from prediabetes to type 2 diabetes and reduce heart risk. It is for Hispanic adults who are overweight and have prediabetes.
San Antonio, TexasAges 18 years+ - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Palo Alto, CaliforniaAges 18–55
Hear when a new Coronary Artery Disease Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for coronary artery disease progression?
- Yes. Clin2 currently lists 42 recruiting coronary artery disease progression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a coronary artery disease progression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a coronary artery disease progression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.